Pharmacological Treatment Patterns at Study Entry for the First 500 STEP-BD Participants

Area of Science:

• Psychiatry and Clinical Psychology
• Pharmacology
• Neuroscience

Background:

• Bipolar disorder is a complex mood disorder requiring effective psychopharmacological management.
• Understanding current treatment patterns is crucial for optimizing patient care and guiding future research.

Purpose of the Study:

• To assess the psychopharmacological treatment patterns for bipolar disorder in a large patient cohort.
• To analyze prescribing trends based on illness subtype and compare them with other settings.

Main Methods:

• Examined intake treatment data from the first 500 patients in the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD) study.
• Utilized the Structured Clinical Interview for DSM-IV mood modules for diagnosis.
• Collected treatment data through initial psychiatric examination interviews.

Main Results:

• Standard mood stabilizers (lithium, valproate, carbamazepine) were most common (71.9%), followed by antidepressants (40.6%), novel anticonvulsants (31.8%), and second-generation neuroleptics (27.2%).
• A significant proportion of patients (63.4%) were euthymic at intake, while others presented with depressive (24.6%) or manic/hypomanic/mixed (12.0%) states.
• Only 11% of patients received standard mood stabilizer monotherapy, indicating polypharmacy is common.

Conclusions:

• Standard mood stabilizers are the primary treatment for bipolar disorder in academic psychiatric settings, supplemented by antidepressants and newer agents.
• Findings provide insight into the current standard of care and identify areas lacking evidence for clinical practice.
• Further research on longitudinal prescribing patterns in bipolar disorder is warranted.